Suppr超能文献

食物对口服曲马多-塞来昔布共晶(CTC)后曲马多和塞来昔布生物利用度的影响:一项在健康志愿者中进行的随机、开放标签、单剂量、交叉研究。

The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers.

机构信息

Esteve Pharmaceuticals, S.A., Parc Cientific Barcelona C/ Baldiri Reixac 4-8, 08028, Barcelona, Spain.

Algorithme Pharma, 575 Armand-Frappier Boulevard, Laval, Quebec, H7V 4B3, Canada.

出版信息

Clin Drug Investig. 2018 Sep;38(9):819-827. doi: 10.1007/s40261-018-0672-y.

Abstract

BACKGROUND AND OBJECTIVE

Co-Crystal of Tramadol-Celecoxib (CTC), in development for the treatment of moderate to severe acute pain, is a first-in-class co-crystal containing a 1:1 molecular ratio of two active pharmaceutical ingredients; rac-tramadol·HCl and celecoxib. This randomised, open-label, crossover study compared the bioavailability of both components after CTC administration under fed and fasting conditions.

METHODS

Healthy adults received single doses of 200 mg CTC under both fed and fasting conditions (separated by a 7-day washout). Each dose of CTC was administered orally as two 100 mg tablets, each containing 44 mg tramadol·HCl and 56 mg celecoxib. In the fed condition, a high-fat, high-calorie meal [in line with recommendations by the US Food and Drug Administration (FDA)] was served 30 min before CTC administration. Tramadol, O-desmethyltramadol and celecoxib plasma concentrations were measured pre- and post-dose up to 48 h. Pharmacokinetic parameters were calculated using non-compartmental analysis. Safety was also assessed.

RESULTS

Thirty-six subjects (18 female/18 male) received one or both doses of CTC; 33 provided evaluable pharmacokinetic data under fed and fasting conditions. For tramadol and O-desmethyltramadol, fed-to-fasting ratios of geometric least-squares means and corresponding 90% confidence interval (CI) values for maximum plasma concentration (C) and extrapolated area under the plasma concentration-time curve to infinity (AUC) were within the pre-defined range for comparative bioavailability (80-125%). For celecoxib, C and AUC fed-to-fasting ratios (90% CIs) were outside this range, at 130.91% (116.98-146.49) and 129.34% (121.78-137.38), respectively. The safety profile of CTC was similar in fed and fasting conditions.

CONCLUSIONS

As reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose CTC. Food had no effect on tramadol or O-desmethyltramadol bioavailability.

CLINICAL TRIAL REGISTRATION NUMBER

152052 (registered with the Therapeutic Products Directorate of Health Canada).

摘要

背景和目的

曲马多-塞来昔布共晶(CTC)正在开发用于治疗中重度急性疼痛,是首个含有两种活性药物成分(rac-盐酸曲马多和塞来昔布)的 1:1 分子比例的共晶药物。本随机、开放标签、交叉研究比较了 CTC 在进食和禁食条件下给药后两种成分的生物利用度。

方法

健康成年人在进食和禁食条件下各接受单剂量 200mg CTC(间隔 7 天洗脱期)。每次 CTC 剂量均口服给予两片 100mg 片剂,每片含有 44mg 盐酸曲马多和 56mg 塞来昔布。在进食条件下,在给予 CTC 前 30 分钟给予高脂肪、高热量膳食[符合美国食品和药物管理局(FDA)的建议]。在给药前和给药后 48 小时内测量曲马多、O-去甲基曲马多和塞来昔布的血浆浓度。使用非房室分析计算药代动力学参数。还评估了安全性。

结果

36 名受试者(18 名女性/18 名男性)接受了 CTC 的一次或两次剂量;33 名受试者在进食和禁食条件下提供了可评估的药代动力学数据。对于曲马多和 O-去甲基曲马多,最大血浆浓度(C)和血浆浓度-时间曲线下面积至无穷大(AUC)的几何最小二乘均值和相应 90%置信区间(CI)的进食-禁食比值在可比较生物利用度的预定范围内(80-125%)。对于塞来昔布,C 和 AUC 的进食-禁食比值(90%CI)超出该范围,分别为 130.91%(116.98-146.49)和 129.34%(121.78-137.38)。CTC 的安全性在进食和禁食条件下相似。

结论

与标准制剂塞来昔布报告的情况一样,食物增加了单次 CTC 给药后塞来昔布的生物利用度。食物对曲马多或 O-去甲基曲马多的生物利用度没有影响。

临床试验注册号

152052(在加拿大卫生部治疗产品管理局注册)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a623/6153956/378fe72dff18/40261_2018_672_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验